Martin Münchbach is a venture capital investor since 1999, investing in life science companies across all stages and types. Joined Bellevue Group in 2004. Martin’s investments and board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer, Axovan and Glycart. PhD Protein Chemist & Biochemist.
Current role